{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:58:05Z","timestamp":1789995485462,"version":"4.0.1"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Belgian National Fund for Scientific Research","doi-asserted-by":"publisher","award":["FNRS-FC 43697"],"award-info":[{"award-number":["FNRS-FC 43697"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, and progressive interstitial lung disease with an average survival of approximately 3\u2009years. The evolution of IPF is unpredictable, with some patients presenting a relatively stable condition with limited progression over time, whereas others deteriorate rapidly. In addition to IPF, other interstitial lung diseases can lead to pulmonary fibrosis, and up to a third have a progressive phenotype with the same prognosis as IPF. Clinical, biological, and radiological risk factors of progression were identified, but no specific biomarkers of fibrogenesis are currently available. A recent interest in the fibroblast activation protein alpha (FAP\u03b1) has emerged. FAP\u03b1 is a transmembrane serine protease with extracellular activity. It can also be found in a soluble form, also named anti-plasmin cleaving enzyme (APCE). FAP\u03b1 is specifically expressed by activated fibroblasts, and quinoline-based specific inhibitors (FAPI) were developed, allowing us to visualize its distribution\n                    <jats:italic>in vivo<\/jats:italic>\n                    by imaging techniques. In this review, we discuss the use of FAP\u03b1 as a useful biomarker for the progression of lung fibrosis, by both its assessment in human fluids and\/or its detection by imaging techniques and immunohistochemistry.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2024.1393778","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:41:00Z","timestamp":1726706460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Philom\u00e8ne","family":"Lavis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Garabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Kupper","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bondue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/rheumatology\/kex077","article-title":"Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study","volume":"57","author":"Reiseter","year":"2018","journal-title":"Rheumatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","article-title":"Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)","volume":"57","author":"Nasser","year":"2021","journal-title":"Eur Respir J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur Respir J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12931-021-01749-1","article-title":"Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)","volume":"22","author":"Nasser","year":"2021","journal-title":"Respir Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1901681","DOI":"10.1183\/13993003.01681-2019","article-title":"Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease","volume":"55","author":"Alfieri","year":"2020","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/thoraxjnl-2017-210035","article-title":"Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis","volume":"73","author":"Gimenez","year":"2018","journal-title":"Thorax"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1335758","DOI":"10.3389\/fmed.2024.1335758","article-title":"Risk factors for progression of pulmonary fibrosis: a single-centered, retrospective study","volume":"11","author":"Fan","year":"2024","journal-title":"Front Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3899\/jrheum.200863","article-title":"Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease","volume":"48","author":"Kronzer","year":"2021","journal-title":"J Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1378\/chest.114.3.801","article-title":"African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease","volume":"114","author":"Greidinger","year":"1998","journal-title":"Chest"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0925-4439(97)00032-x","article-title":"Molecular cloning of seprase: a serine integral membrane protease from human melanoma","volume":"1361","author":"Goldstein","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"7595","DOI":"10.1074\/jbc.272.12.7595","article-title":"Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease","volume":"272","author":"Pi\u00f1eiro-S\u00e1nchez","year":"1997","journal-title":"J Biol Chem"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.biocel.2004.05.006","article-title":"Purification, identification and characterisation of seprase from bovine serum","volume":"36","author":"Collins","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1006\/prep.2001.1572","article-title":"Expression, purification, and kinetic characterization of full-length human fibroblast activation protein","volume":"24","author":"Sun","year":"2002","journal-title":"Protein Expr Purif"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1742-4658.2011.08051.x","article-title":"Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-\u03b1","volume":"278","author":"Keane","year":"2011","journal-title":"FEBS J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","article-title":"Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21","volume":"291","author":"Dunshee","year":"2016","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1042\/BJ20151085","article-title":"Circulating FGF21 proteolytic processing mediated by fibroblast activation protein","volume":"473","author":"Zhen","year":"2016","journal-title":"Biochem J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.abb.2006.11.006","article-title":"Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV","volume":"457","author":"Christiansen","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1182\/blood-2005-08-3452","article-title":"Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein","volume":"107","author":"Lee","year":"2006","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1182\/blood-2003-12-4240","article-title":"A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1046\/j.1432-1327.1998.2540650.x","article-title":"Mouse fibroblast-activation protein--conserved Fap gene organization and biochemical function as a serine protease","volume":"254","author":"Niedermeyer","year":"1998","journal-title":"Eur J Biochem"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ijc.2910580314","article-title":"Fibroblast activation protein: purification, epitope mapping and induction by growth factors","volume":"58","author":"Rettig","year":"1994","journal-title":"Int J Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/hep.510290631","article-title":"Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis","volume":"29","author":"Levy","year":"1999","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00403-010-1084-x","article-title":"Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option","volume":"302","author":"Dienus","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1164\/rccm.202110-2414OC","article-title":"Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases","volume":"207","author":"Yang","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/odi.14602","article-title":"Fibroblast activating protein promotes the proliferation, migration, and activation of fibroblasts in oral submucous fibrosis","volume":"30","author":"Li","year":"2023","journal-title":"Oral Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.yexmp.2009.09.001","article-title":"TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM","volume":"87","author":"Chen","year":"2009","journal-title":"Exp Mol Pathol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3892\/ijo.2011.1002","article-title":"Ultraviolet exposure of melanoma cells induces fibroblast activation protein-\u03b1 in fibroblasts: implications for melanoma invasion","volume":"39","author":"W\u00e4ster","year":"2011","journal-title":"Int J Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ijc.23871","article-title":"Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells","volume":"124","author":"Kennedy","year":"2009","journal-title":"Int J Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.matbio.2017.12.003","article-title":"Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts","volume":"67","author":"Avery","year":"2018","journal-title":"Matrix Biol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.humpath.2005.11.020","article-title":"Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis","volume":"37","author":"Acharya","year":"2006","journal-title":"Hum Pathol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s10529-015-1855-8","article-title":"Luciferase expression is driven by the promoter of fibroblast activation protein-\u03b1 in murine pulmonary fibrosis","volume":"37","author":"Wenlong","year":"2015","journal-title":"Biotechnol Lett"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"8070","DOI":"10.1074\/jbc.M115.701433","article-title":"Fibroblast activation protein (FAP) accelerates collagen degradation and clearance from lungs in mice","volume":"291","author":"Fan","year":"2016","journal-title":"J Biol Chem"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1164\/rccm.200505-717OC","article-title":"Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model","volume":"173","author":"Chaudhary","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"L152","DOI":"10.1152\/ajplung.00313.2007","article-title":"Murine models of pulmonary fibrosis","volume":"294","author":"Moore","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4939-7113-8_2","article-title":"The bleomycin model of pulmonary fibrosis","volume":"1627","author":"Liu","year":"2017","journal-title":"Methods Mol Biol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"L271","DOI":"10.1152\/ajplung.00071.2019","article-title":"Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-\u03b2 and chronic bleomycin-induced fibrosis","volume":"317","author":"Kimura","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"L442","DOI":"10.1152\/ajplung.00026.2010","article-title":"Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis","volume":"299","author":"Degryse","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejphar.2017.05.022","article-title":"Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis","volume":"809","author":"Egger","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/13543784.16.9.1459","article-title":"Talabostat","volume":"16","author":"Cunningham","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jcmgh.2022.12.005","article-title":"Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis","volume":"15","author":"Yang","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"104766","DOI":"10.1016\/j.ebiom.2023.104766","article-title":"Precision medicine advances in idiopathic pulmonary fibrosis","volume":"95","author":"Karampitsakos","year":"2023","journal-title":"EBioMedicine"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12931-023-02556-6","article-title":"Usefulness of FAP\u03b1 assessment in bronchoalveolar lavage as a marker of fibrogenesis: results of a preclinical study and first report in patients with idiopathic pulmonary fibrosis","volume":"24","author":"Lavis","year":"2023","journal-title":"Respir Res"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1183\/13993003.congress-2022.510","article-title":"Fibroblast activation protein and disease severity, progression and survival in IPF","author":"Prior","year":"2022","journal-title":"Eur Respir J"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e0178987","DOI":"10.1371\/journal.pone.0178987","article-title":"Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease","volume":"12","author":"Uitte de Willige","year":"2017","journal-title":"PLoS One"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.diabres.2015.02.024","article-title":"Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity","volume":"108","author":"Williams","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.fob.2013.12.001","article-title":"Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs","volume":"4","author":"Keane","year":"2013","journal-title":"FEBS Open Bio"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijcard.2014.10.091","article-title":"Plasma levels of soluble fibroblast activation protein in arterial thrombosis: determinants and cleavage of its substrate alpha-2-antiplasmin","volume":"178","author":"Uitte de Willige","year":"2015","journal-title":"Int J Cardiol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1111\/1756-185X.13031","article-title":"Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis","volume":"21","author":"Sinnathurai","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00296-023-05499-9","article-title":"Serum IL-17 and TNF\u03b1 as prognostic biomarkers in systemic sclerosis patients: a prospective study","volume":"44","author":"Kosa\u0142ka-W\u0119giel","year":"2023","journal-title":"Rheumatol Int"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00259-023-06107-5","article-title":"[68Ga]Ga-FAPI-04 PET\/CT on assessing Crohn\u2019s disease intestinal lesions","volume":"50","author":"Chen","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e222052","DOI":"10.1148\/radiol.222052","article-title":"68Ga-FAPI PET\/CT for rheumatoid arthritis: a prospective study","volume":"307","author":"Luo","year":"2023","journal-title":"Radiology"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11886-023-01869-8","article-title":"The potential of fibroblast activation protein-targeted imaging as a biomarker of cardiac remodeling and injury","volume":"25","author":"Mayola","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.121.261925","article-title":"Fibroblast activation protein-specific PET\/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study","volume":"63","author":"R\u00f6hrich","year":"2022","journal-title":"J Nucl Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00259-023-06564-y","article-title":"Initial results with [18F]FAPI-74 PET\/CT in idiopathic pulmonary fibrosis","volume":"51","author":"Mori","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","article-title":"68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study","volume":"3","author":"Bergmann","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00259-022-06081-4","article-title":"Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT","volume":"50","author":"Treutlein","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/RLU.0000000000004437","article-title":"Enhancing clinical diagnosis for patients with persistent pulmonary abnormalities after COVID-19 infection: the potential benefit of 68 Ga-FAPI PET\/CT","volume":"47","author":"Sviridenko","year":"2022","journal-title":"Clin Nucl Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3390\/ph16101434","article-title":"99mTc-labeled FAPI SPECT imaging in idiopathic pulmonary fibrosis: preliminary results","volume":"16","author":"Liu","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1007\/s00259-022-05814-9","article-title":"[68Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity","volume":"49","author":"Rosenkrans","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1177\/03635465231208843","article-title":"Fibroblast activation protein-targeted PET\/CT with Al18F-NODA-FAPI-04 for in vivo imaging of tendon healing in rat achilles tendon injury models","volume":"51","author":"Liu","year":"2023","journal-title":"Am J Sports Med"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/annrheumdis-2020-217408","article-title":"Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging","volume":"79","author":"Schmidkonz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s11739-023-03327-3","article-title":"Assessment of pulmonary fibrosis induced by paraquat using Al18F-NODA-FAPI-04 PET\/CT","volume":"18","author":"Song","year":"2023","journal-title":"Intern Emerg Med"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41824-018-0045-z","article-title":"Assessment of 18F-FDG uptake in idiopathic pulmonary fibrosis: influence of lung density changes","volume":"2","author":"Castiaux","year":"2018","journal-title":"Eur J Hybrid Imaging"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12931-019-0974-5","article-title":"Absence of early metabolic response assessed by 18F-FDG PET\/CT after initiation of antifibrotic drugs in IPF patients","volume":"20","author":"Bondue","year":"2019","journal-title":"Respir Res"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2310\/7290.2011.00030","article-title":"Novel positron emission tomography\/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[18F]fluoro-D-glucose","volume":"11","author":"Win","year":"2012","journal-title":"Mol Imaging"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/thx.2007.078006","article-title":"Activation of somatostatin receptors attenuates pulmonary fibrosis","volume":"63","author":"Borie","year":"2008","journal-title":"Thorax"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/thoraxjnl-2018-211851","article-title":"Hyperpolarised xenon magnetic resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in IPF","volume":"74","author":"Weatherley","year":"2019","journal-title":"Thorax"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"00048-2023","DOI":"10.1183\/23120541.00048-2023","article-title":"Hyperpolarised xenon-129 diffusion-weighted magnetic resonance imaging for assessing lung microstructure in idiopathic pulmonary fibrosis","volume":"9","author":"Eaden","year":"2023","journal-title":"ERJ Open Res"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41379-021-00889-5","article-title":"The histologic diagnosis of usual interstitial pneumonia of idiopathic pulmonary fibrosis. Where we are and where we need to go","volume":"35","author":"Smith","year":"2022","journal-title":"Mod Pathol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/labinvest.2016.135","article-title":"Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis","volume":"97","author":"Yamaguchi","year":"2017","journal-title":"Lab Investig"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.29245\/2689-999X\/2019\/2.1149","article-title":"Epithelial-mesenchymal transition contributes to pulmonary fibrosis via aberrant epithelial\/fibroblastic cross-talk","volume":"3","author":"Hill","year":"2019","journal-title":"J Lung Health Dis"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1440-1843.2012.02272.x","article-title":"Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non-specific interstitial pneumonia","volume":"18","author":"Harada","year":"2013","journal-title":"Respirology"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.humpath.2020.10.008","article-title":"Artificial intelligence identifies inflammation and confirms fibroblast foci as prognostic tissue biomarkers in idiopathic pulmonary fibrosis","volume":"107","author":"M\u00e4kel\u00e4","year":"2021","journal-title":"Hum Pathol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2559.2006.02554.x","article-title":"Organizing pneumonia and lymphoplasmacytic inflammation predict treatment response in idiopathic pulmonary fibrosis","volume":"50","author":"Collard","year":"2007","journal-title":"Histopathology"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein Inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.chest.2020.04.066","article-title":"Circulating plasma biomarkers of survival in antifibrotic-treated patients with idiopathic pulmonary fibrosis","volume":"158","author":"Adegunsoye","year":"2020","journal-title":"Chest"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.arbres.2019.08.020","article-title":"Clinical research on prognostic evaluation of subjects with IPF by peripheral blood biomarkers, quantitative imaging characteristics and pulmonary function parameters","volume":"56","author":"Guo","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"4759040","DOI":"10.1155\/2016\/4759040","article-title":"Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis","volume":"2016","author":"Hamai","year":"2016","journal-title":"Dis Markers"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.chest.2018.08.1083","article-title":"Idiopathic pulmonary fibrosis: prospective, case-controlled study of natural history and circulating biomarkers","volume":"154","author":"Raghu","year":"2018","journal-title":"Chest"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1515\/cclm-2021-0199","article-title":"Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"59","author":"Aloisio","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10753-018-00955-2","article-title":"Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP","volume":"42","author":"Bennett","year":"2019","journal-title":"Inflammation"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.resinv.2019.02.001","article-title":"Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib","volume":"57","author":"Bergantini","year":"2019","journal-title":"Respir Investig"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"L3","DOI":"10.1152\/ajplung.90637.2008","article-title":"Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis","volume":"299","author":"Collard","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.rmed.2017.08.021","article-title":"Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone","volume":"131","author":"Ikeda","year":"2017","journal-title":"Respir Med"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12931-020-01582-y","article-title":"Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan","volume":"21","author":"Ikeda","year":"2020","journal-title":"Respir Res"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.21037\/jtd.2018.07.76","article-title":"Sequential changes of serum KL-6 predict the progression of interstitial lung disease","volume":"10","author":"Jiang","year":"2018","journal-title":"J Thorac Dis"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1378\/chest.11-2735","article-title":"Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis","volume":"143","author":"Song","year":"2013","journal-title":"Chest"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.resinv.2016.09.003","article-title":"Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis","volume":"55","author":"Wakamatsu","year":"2017","journal-title":"Respir Investig"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12890-020-1060-y","article-title":"Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis","volume":"20","author":"Yoshikawa","year":"2020","journal-title":"BMC Pulm Med"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1440-1843.2006.00834.x","article-title":"Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis","volume":"11","author":"Yokoyama","year":"2006","journal-title":"Respirology"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"00074-2016","DOI":"10.1183\/23120541.00074-2016","article-title":"MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis","volume":"3","author":"Bauer","year":"2017","journal-title":"ERJ Open Res"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"3424208","DOI":"10.1155\/2020\/3424208","article-title":"Prognostic value of serum Osteopontin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"2020","author":"Gui","year":"2020","journal-title":"Biomed Res Int"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1378\/chest.08-2209","article-title":"Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis","volume":"135","author":"Kinder","year":"2009","journal-title":"Chest"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1164\/ajrccm.162.3.9910080","article-title":"Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent","volume":"162","author":"Takahashi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"e7083","DOI":"10.1097\/MD.0000000000007083","article-title":"Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1393778\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:41:02Z","timestamp":1726706462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1393778\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":107,"alternative-id":["10.3389\/fmed.2024.1393778"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1393778","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"1393778"}}